A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease

PHASE3RecruitingINTERVENTIONAL
Enrollment

162

Participants

Timeline

Start Date

November 13, 2023

Primary Completion Date

May 30, 2026

Study Completion Date

June 30, 2026

Conditions
Behçet's Disease
Interventions
DRUG

Hemay005

Hemay005 tables 60mg bid p.o;

DRUG

Hemay005

Hemay005 tables 45mg bid p.o;

DRUG

Placebo

placebo to Hemay005 tables bid p.o

Trial Locations (22)

Unknown

RECRUITING

Beijing Friendship hospital capital medical hospital, Beijing

RECRUITING

Peking university first hospital, Beijing

RECRUITING

Peking University People's Hospital, Beijing

RECRUITING

Peking university third hospital, Beijing

RECRUITING

Xuanwu hospital capital medical university, Beijing

RECRUITING

The first affiliated hospital of Xiamen University, Xiamen

RECRUITING

Guangdong second provincial central hospital, Guangzhou

RECRUITING

Sun Yat-Sen memorial hospital, Guangzhou

RECRUITING

The third affiliated hospital sun yat-sen university, Guangzhou

RECRUITING

The university of Hong Kong-Shenzhen Hospital, Shenzhen

RECRUITING

Affiliated hospital of Guilin Medical university, Guilin

NOT_YET_RECRUITING

The second hospital of Hebei medical university, Shijiazhuang

RECRUITING

Xinxiang Central hospital, Xinxiang

RECRUITING

The first affiliated hospital of Nanchang university, Nanchang

RECRUITING

The first affiliated hospital of Soochow university, Suzhou

RECRUITING

The affiliated hospital of Xuzhou medical university, Xuzhou

RECRUITING

Jilin Province People's hospital, Changchun

NOT_YET_RECRUITING

Linyi People's Hospital, Linyi

RECRUITING

Tongji hospital of Tongji university, Shanghai

NOT_YET_RECRUITING

Second hospital of shanxi medical university, Taiyuan

RECRUITING

The first affiliated hospital, Zhejiang University school of medicine, Hangzhou

RECRUITING

The first affiliated hospital of Wenzhou Medical university, Wenzhou

All Listed Sponsors
lead

Ganzhou Hemay Pharmaceutical Co., Ltd

INDUSTRY

NCT06145893 - A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease | Biotech Hunter | Biotech Hunter